Astellas Pharma Inc. (JOBS) Fails to Get Injunction vs FDA Over Prograf

Bookmark and Share

Reuters -- Japan's Astellas Pharma said on Thursday a U.S. court has rejected its request for an injunction to prevent the Food and Drug Administration from approving generic products to its top-selling Prograf transplant drug.
MORE ON THIS TOPIC